CRL vs NPACU
Charles River Laboratories (CRL) versus New Providence Acquisition Corp. III Units (NPACU) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
New Providence Acquisition Corp. III Units (NPACU) is a shell companies company listed on NASDAQ.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
NPACU does not have a complete income-statement cache yet.
CRL currently screens at market cap $7.78B. NPACU currently screens at market cap $0.
Not investment advice. Open the CRL and NPACU stock pages for the full models.
Not investment advice.